Tailor-made Antibodies
and Tools for Life Science
quick order | cart
?
|
login
Home|||||Technical Support
Home > Products > 177 003

P2X7 antibody - 177 003 K.O.

P2X7 is a ionotropic ATP-gated cation channels receptor
Rabbit polyclonal purified antibody
Cat. No.: 177 003
Amount: 50 µg
Price: $375.00
Cat. No. 177 003 50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin was added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 1000 (AP staining) (see remarks) gallery  
IP: not tested yet
ICC: not tested yet
IHC: not tested yet
IHC-P: not tested yet
Immunogen Recombinant protein corresponding to AA 363 to 595 from mouse P2X7 (UniProt Id: Q9Z1M0)
Reactivity Reacts with: rat (Q64663), mouse (Q9Z1M0).
Other species not tested yet.
Specificity K.O. validated PubMed: 25700737
Remarks

Detects mouse protein with higher sensitivity.
WB: This antibody detects an additional band at 30 kDa of unknown identity.
Data sheet 177_003.pdf

References for P2X7 - 177 003

P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH, Róg J, Chira N, Kao AP, Al-Khalidi R, Górecki DC
Frontiers in pharmacology (2022) 13: 935804. 177 003 WB, ICC; KO verified; tested species: mouse
iTRAQ-based proteomics implies inflammasome pathway activation in the prefrontal cortex of CSDS mice may influence resilience and susceptibility.
Lan T, Bai M, Chen X, Wang Y, Li Y, Tian Y, He Y, Wu Z, Yu H, Chen Z, Chen C, et al.
Life sciences (2020) 262: 118501. 177 003 WB; tested species: mouse
Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody.
Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, Bruzzone S, Engel T, Jooss T, Krautloher A, Schuster S, et al.
eLife (2018) 7: . 177 003 WB, IHC; tested species: mouse
Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition.
Young CNJ, Chira N, Róg J, Al-Khalidi R, Benard M, Galas L, Chan P, Vaudry D, Zablocki K, Górecki DC
Journal of molecular cell biology (2017) : . 177 003 WB; tested species: mouse
A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, Gorecki DC
Autophagy (2015) 111: 113-30. 177 003 WB; KO verified
P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, et al.
PLoS medicine (2015) 1210: e1001888. 177 003 ICC, WB
Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts.
Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, Murrell-Lagnado R
British journal of pharmacology (2012) 1654: 978-93. 177 003 WB
P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment.
Young CN, Brutkowski W, Lien CF, Arkle S, Lochmüller H, Zabłocki K, Górecki DC
Journal of cellular and molecular medicine (2012) 165: 1026-37. 177 003 WB
P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH, Róg J, Chira N, Kao AP, Al-Khalidi R, Górecki DC
Frontiers in pharmacology (2022) 13: 935804. 177 003 WB, ICC; KO verified; tested species: mouse
P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, et al.
PLoS medicine (2015) 1210: e1001888. 177 003 ICC, WB
Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody.
Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, Bruzzone S, Engel T, Jooss T, Krautloher A, Schuster S, et al.
eLife (2018) 7: . 177 003 WB, IHC; tested species: mouse
Cat. No.: 177 003
Amount: 50 µg
Price: $375.00
P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH, Róg J, Chira N, Kao AP, Al-Khalidi R, Górecki DC
Frontiers in pharmacology (2022) 13: 935804. 177 003 WB, ICC; KO verified; tested species: mouse
iTRAQ-based proteomics implies inflammasome pathway activation in the prefrontal cortex of CSDS mice may influence resilience and susceptibility.
Lan T, Bai M, Chen X, Wang Y, Li Y, Tian Y, He Y, Wu Z, Yu H, Chen Z, Chen C, et al.
Life sciences (2020) 262: 118501. 177 003 WB; tested species: mouse
Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody.
Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, Bruzzone S, Engel T, Jooss T, Krautloher A, Schuster S, et al.
eLife (2018) 7: . 177 003 WB, IHC; tested species: mouse
Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition.
Young CNJ, Chira N, Róg J, Al-Khalidi R, Benard M, Galas L, Chan P, Vaudry D, Zablocki K, Górecki DC
Journal of molecular cell biology (2017) : . 177 003 WB; tested species: mouse
A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, Gorecki DC
Autophagy (2015) 111: 113-30. 177 003 WB; KO verified
P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, et al.
PLoS medicine (2015) 1210: e1001888. 177 003 ICC, WB
Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts.
Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, Murrell-Lagnado R
British journal of pharmacology (2012) 1654: 978-93. 177 003 WB
P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment.
Young CN, Brutkowski W, Lien CF, Arkle S, Lochmüller H, Zabłocki K, Górecki DC
Journal of cellular and molecular medicine (2012) 165: 1026-37. 177 003 WB
P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH, Róg J, Chira N, Kao AP, Al-Khalidi R, Górecki DC
Frontiers in pharmacology (2022) 13: 935804. 177 003 WB, ICC; KO verified; tested species: mouse
P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, et al.
PLoS medicine (2015) 1210: e1001888. 177 003 ICC, WB
Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody.
Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, Bruzzone S, Engel T, Jooss T, Krautloher A, Schuster S, et al.
eLife (2018) 7: . 177 003 WB, IHC; tested species: mouse
WB
Background
Neurotransmitters are released from synaptic vesicles into the synaptic cleft where they can bind to neurotransmitter receptors located in the plasma membrane. Purines can act as neurotransmitters and the corresponding receptors can be subdivided into two families: P1 receptors are sensitive to adenosine while P2 receptors are triggered by ATP.
The P2 receptor family is composed of two major groups, the metabotrophic G protein coupled P2Y receptors and the ionotrophic ATP-gated cation channels receptors P2X. Seven P2X receptors have been identified so far which all share a similar transmembrane topology. They consist of N- and C-termini facing the cytoplasm, two transmembrane spanning domains and a large extracellular loop. Compared to P2X1-6 P2X7 has a much longer cytoplasmic C-terminal tail. The P2X1-7 receptors are able to form hetero- or homo-multimers. The tissue distribution and function of P2X7 is still under discussion.